FDA
-
-
-
-
-
-
-
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
-
-
-
-
-
-
-
Arcutis Biotherapeutics (ARQT) Announces Pricing of $150 Mln Public Offering
-
-
-
-
-
-
-
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
-
-
-
-
-
-
-
Arcutis Biotherapeutics (ARQT) Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial
-
-
-
-
-
-
-
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
-
-
-
-
-
-
-
Arcutis Biotherapeutics (ARQT) Announces Leadership Transition
-
251,395 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All